Switch to Jennifer Shabbits's research page...

In Press

1. Gelmon KA, Stewart D, Chi K, Chia S, Janke S, Ayers D, Walsh W, McIntosh L, Shabbits JA, Seymour LK. A phase 1 study of ZD0473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer. A National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) trial IND 131. Annals of Oncology (In Press).
    Request Paper

2004

2. Lincoln A. Edwards, Jennifer A. Shabbits, Marcel Bally, Shoukat Dedhar. Integrin-linked kinase (ILK) in combination molecular targeting Cancer Treatment and Research: Molecular Targeting and Signal Transduction (2004).
    Request Paper

2003

3. Shabbits JA and Mayer LD. High ceramide content liposomes with in vivo antitumor activity Anticancer Research (2003).
    Request Paper

4. Shabbits JA and Mayer LD. Intracellular delivery of ceramide via liposomes induces apoptosis in vitro Biochemica et Biophysica Acta (2003).
    Request Paper

5. Shabbits JA, Hu Y and Mayer LD. Tumor chemosensitization strategies based on apoptosis manipulations Molecular Cancer Therapeutics (2003).
    Request Paper

2002

6. Shabbits JA and Mayer LD. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs Molecular Cancer Therapeutics (2002).
    Request Paper

7. Shabbits JA, Chiu GN and Mayer LD. Development of an in vitro exchange assay that accurately predicts in vivo drug retention for liposome-based delivery systems Journal of Controlled Release (2002).
    Request Paper

2001

8. Jennifer A. Shabbits, Rajesh Krishna and Lawrence D. Mayer. Molecular and pharmacological strategies to overcome multidrug resistance Expert Review of Anticancer Therapy (2001).
    Request Paper

9. LD Mayer and JA Shabbits. The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance Cancer and Metastasis Reviews (2001).
    Request Paper

1999

10. Lawrence D Mayer, Jennifer Reamer, and Marcel B. Bally. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. Journal of Pharmaceutical Sciences 88: 96-102 (1999).
     Request Paper

2003

1. LD Mayer, JA Shabbits and MB Bally . Enhanced Delivery of Sphingolipids Provisional Canadian and US Patent (2003).
    Request Paper